<DOC>
	<DOCNO>NCT01568021</DOCNO>
	<brief_summary>This multicenter observational study ass efficacy tolerability OZURDEX® clinical practice , assess time patient consider retreatment .</brief_summary>
	<brief_title>Post Market Surveillance OZURDEX® Branch Retinal Vein Occlusion ( BRVO ) Central Retinal Vein Occlusion ( CRVO )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Macular Edema Prescribed OZURDEX®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>